Neoadjuvant Therapy for HR+ Breast Cancer

In this program Atish D. Choudhury, MD, PhD, discusses recent updates on long-term safety and efficacy data in patients with metastatic castration-sensitive prostate cancer and the importance of patient communication and quality of life while on treatment.

This article reviews emerging evidence on PARP inhibitors as first-line maintenance treatment options after chemotherapy and features expert insights from Rebecca Previs, MD.